Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/176191
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mesía Nin, Ricard | - |
dc.contributor.author | Iglesias, L. | - |
dc.contributor.author | Lambea, Julio | - |
dc.contributor.author | Martínez Trufero, J. | - |
dc.contributor.author | Soria, A. | - |
dc.contributor.author | Taberna, Miren | - |
dc.contributor.author | Trigo, J. | - |
dc.contributor.author | Chaves, M. | - |
dc.contributor.author | García Castaño, A. | - |
dc.contributor.author | Cruz, J. | - |
dc.date.accessioned | 2021-04-12T15:28:50Z | - |
dc.date.available | 2021-04-12T15:28:50Z | - |
dc.date.issued | 2021-02-26 | - |
dc.identifier.uri | https://hdl.handle.net/2445/176191 | - |
dc.description.abstract | Head and neck cancers (HNC) are defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2017 publication, the Spanish Society of Medical Oncology (SEOM) presents an update of the squamous cell HNC diagnosis and treatment guideline. Most relevant diagnostic and therapeutic changes from the last guideline have been updated: introduction of sentinel node biopsy in early oral/oropharyngeal cancer treated with surgery, concomitant radiotherapy with weekly cisplatin 40 mg/m2 in the adjuvant setting, new approaches for HPV-related oropharyngeal cancer and new treatments with immune-checkpoint inhibitors in recurrent/metastatic disease. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Nature | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1007/s12094-020-02533-1 | - |
dc.relation.ispartof | Clinical and Translational Oncology, 2021 | - |
dc.relation.uri | https://doi.org/10.1007/s12094-020-02533-1 | - |
dc.rights | cc by (c) Mesia et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de coll | - |
dc.subject.classification | Càncer de cap | - |
dc.subject.classification | Immunoteràpia | - |
dc.subject.classification | Papil·lomavirus | - |
dc.subject.other | Neck cancer | - |
dc.subject.other | Head cancer | - |
dc.subject.other | Immunotherapy | - |
dc.subject.other | Papillomaviruses | - |
dc.title | SEOM clinical guidelines for the treatment of head and neck cancer (2020) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-03-24T08:02:50Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33635468 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Mesia2021_Article_SEOMClinicalGuidelinesForTheTr.pdf | 727.11 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License